Phatak, P., Brissot, P., Wurster, M., et al. (2010) A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology, 52, 1671-1779. doi:10.1002/hep.23879

has been cited by the following article:

• TITLE: Efficacy of deferasirox for the treatment of iron overload in a child affected by Juvenile Hemochromatosis

  AUTHORS: Nicoletta Masera, Alessandro Cattoni, Valentina Decimi, Valeria D’Apolito, Cristina Arosio, Raffaella Mariani, Alberto Piperno

  KEYWORDS: Juvenile Hemochromatosis; Deferasirox; Iron Chelation; Child; Iron Overload

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.2 No.2, May 9, 2013

  ABSTRACT: We report the case of a 7 years old girl with Juvenile Hemochromatosis, due to homozygous mutation of HJV, which had increased serum iron indices and liver iron overload in the absence of any clinical sign of disease. Oral iron chelation with low dose deferasirox showed good efficacy and no side effects. The oral iron chelator deferasirox could be a valid option for removing excess iron in early Juvenile Hemochromatosis.